Welcome to the International Workshop on
Alzheimer’s Disease and HHV-6A & HHV-7

Monday, June 24, 2019
8:30am – 7:15pm
Hotel Le Concorde Quebec
Quebec City, Canada
Registration Fee $150
*Full-Conference registration options include access to Alzheimer’s Disease Workshop
**Price listed is USD

This special one-day workshop will explore recent research implicating a causative role of viruses HHV-6A and HHV-7 in Alzheimer’s Disease. Register for this workshop alone or join the larger International Conference on HHV-6 & HHV-7 being held June 23-26, 2019. Choose your selection on the Registration page. Find more information about the Hotel Le Concorde and full conference schedule.

Keynote speaker: Joel Dudley, PhD, Executive Vice President for Precision Health, Mt Sinai Health System

Senior author: Multiscale Analysis of Independent Alzheimer’s Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus

 

Topics to be covered in the Workshop on Alzheimer’s Disease and HHV-6A & HHV-7

Overview on research implicating HHV-6A and HHV-7 in Alzheimer’s Disease

  • New findings tying roseolovirus to Alzheimer’s disease
  • Abundance of DNA and RNA in AD brain tissue vs controls
  • HHV-6A as a viral mediator in AD
  • Increased abundance of U3/U4 and DR of HHV-6A
  • Suppression of miR-155
  • Specificity of HHV-6A & HHV-7 in AD vs other neurodegenerative diseases
  • Correlation of AD progression with viral abundance

Epidemiology and transmission of HHV-6A and HHV-7

  • What do we know about transmission and prevalence by age of HHV-6A and HHV-7?
  • Implications of infection via olfactory route

HHV-6A & HHV-7 Gene expression relevant to Alzheimer’s Disease

  • Relevance of increased abundance in the HHV-6A U3/U4 genes
  • Viral perturbation of host RFs and TF-Target networks

Other sessions of interest to neurologists new to HHV-6A & HHV-7:

Diagnostic assays

  • New HHV-6A specific serological assays
  • RNA, miRNA assays
  • Other viral markers

Animal models

  • CD46 Transgenic mouse model for HHV-6A
  • Murine roseolovirus impact in established AD models
  • HHV-6A in macaques: what we know

Treatment therapies for HHV-6A and HHV-7

  • Overview of current and pipeline drugs – foscarnet, (val)ganciclovir, IV  brincidofovir, MBX-400, H2G
  • Cytotoxic T cell immunotherapy – Viralym M
  • Neutralizing antibodies
  • Off-patent drugs approved for other uses

HHV-6A in other CNS diseases

  • HHV-6A in MS
  • HHV-6A in other degenerative diseases
  • HHV-6A in CFS/ME